Cann American Corp

PINK:CNNA USA Drug Manufacturers - Specialty & Generic
Market Cap
$1.10 Million
Market Cap Rank
#50476 Global
#15416 in USA
Share Price
$0.00
Change (1 day)
+0.00%
52-Week Range
$0.00 - $0.00
All Time High
$18.40
About

Cann American Corp. is a development stage company dedicated to advancing healthcare solutions through innovative therapies. The company focuses on making healthcare affordable and accessible. By leveraging cutting-edge technology, the company aims to reduce costs and improve the availability of high-quality healthcare services for all patients. The company was formerly known as Canamed4Pets, Inc… Read more

Cann American Corp (CNNA) - Net Assets

Latest net assets as of August 2020: $165.84 USD

Based on the latest financial reports, Cann American Corp (CNNA) has net assets worth $165.84 USD as of August 2020.

Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets ($174.50) and total liabilities ($8.66). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.

Key Net Assets Metrics

Metric Value
Current Net Assets $165.84
% of Total Assets 95.04%
Annual Growth Rate N/A
5-Year Change N/A
10-Year Change -100.25%
Growth Volatility 5779.54

Cann American Corp - Net Assets Trend (2008–2023)

This chart illustrates how Cann American Corp's net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.

Annual Net Assets for Cann American Corp (2008–2023)

The table below shows the annual net assets of Cann American Corp from 2008 to 2023.

Year Net Assets Change
2023-02-28 $-2.81K +57.72%
2022-02-28 $-6.65K -15558.13%
2020-02-29 $42.99 +638.05%
2019-02-28 $-7.99 -1498.00%
2018-02-28 $-0.50 -100.00%
2015-02-28 $33.73K -93.68%
2014-02-28 $533.73K +4.54%
2013-02-28 $510.57K -46.12%
2012-02-29 $947.64K -16.30%
2011-02-28 $1.13 Million +8546.87%
2010-02-28 $-13.40K -1291.90%
2009-02-28 $-963.00 -248.91%
2008-02-29 $-276.00 --

Equity Component Analysis

This analysis shows how different components contribute to Cann American Corp's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.

Equity Composition Insights

  • Retained earnings have grown by 2170800.0% over the analyzed period, indicating profitable operations and earnings retention.

Current Equity Component Breakdown (February 2023)

Component Amount Percentage
Common Stock $947.09 %
Other Components $4.61K %
Total Equity $-2.81K 100.00%

Cann American Corp Competitors by Market Cap

The table below lists competitors of Cann American Corp ranked by their market capitalization.

Equity Growth Attribution

This analysis shows how different factors contributed to changes in Cann American Corp's equity between the two most recent reporting periods.

Equity Growth Insights

  • From 2022 to 2023, total equity changed from -6,645 to -2,810, a change of 3,835.
  • Net income of 3,821 contributed positively to equity growth.
  • Other factors increased equity by 14.

Equity Change Factors (2022 to 2023)

Factor Impact Contribution
Net Income $3.82K +135.98%
Other Changes $14.00 +0.5%
Total Change $- %

Book Value vs Market Value Analysis

This analysis compares Cann American Corp's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.

Valuation Insights

Historical Price-to-Book Ratios

Date Book Value per Share Market Price P/B Ratio
2008-02-29 $-0.07 $0.00 x
2009-02-28 $-0.43 $0.00 x
2010-02-28 $-4.12 $0.00 x
2011-02-28 $357.84 $0.00 x
2012-02-29 $393.05 $0.00 x
2018-02-28 $0.00 $0.00 x
2019-02-28 $0.00 $0.00 x
2020-02-29 $0.00 $0.00 x
2022-02-28 $-0.03 $0.00 x
2023-02-28 $-0.01 $0.00 x

Capital Efficiency Dashboard

This dashboard shows how efficiently Cann American Corp utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.

Capital Efficiency Insights

  • Current Return on Equity (ROE): 0.00%
  • The company may be facing challenges in efficiently utilizing shareholder equity.
  • DuPont Analysis Breakdown:
  • • Net Profit Margin: 0.00%
  • • Asset Turnover: 0.00x
  • • Equity Multiplier: 0.00x
  • Recent ROE (0.00%) is above the historical average (-76.05%), indicating improving capital efficiency.

Historical Capital Efficiency Metrics

Year Return on Equity Net Profit Margin Asset Turnover Equity Multiplier Economic Value Added
2008 0.00% 0.00% 0.00x 0.00x $-11.90K
2009 0.00% 0.00% 0.00x 0.00x $-46.59K
2010 0.00% 0.00% 0.00x 0.00x $-11.10K
2011 -4.01% 0.00% 0.00x 1.06x $-158.60K
2012 -27.92% 0.00% 0.00x 1.26x $-359.34K
2013 -269.10% 0.00% 0.00x 1.80x $-1.42 Million
2014 -32.34% 0.00% 0.00x 1.72x $-225.86K
2018 0.00% -1.95% 0.13x 0.00x $-0.45
2019 0.00% -6.42% 0.60x 0.00x $-6.69
2020 -579.20% -954.02% 0.55x 1.10x $-253.30
2022 0.00% 0.00% 0.00x 0.00x $11.21K
2023 0.00% 0.00% 0.00x 0.00x $4.10K

Industry Comparison

This section compares Cann American Corp's net assets metrics with peer companies in the Drug Manufacturers - Specialty & Generic industry.

Industry Context

  • Industry: Drug Manufacturers - Specialty & Generic
  • Average net assets among peers: $548,450,613
  • Average return on equity (ROE) among peers: -450.37%

Peer Company Comparison

Company Net Assets Return on Equity Debt-to-Equity Market Cap
Cann American Corp (CNNA) $165.84 0.00% 0.05x $38.62
Ascend Wellness Holdings Inc (AAWH) $142.87 Million -33.75% 5.44x $48.90 Million
AB Science S.A (ABSCF) $10.73 Million -252.65% 3.71x $39.89 Million
Alterola Biotech Inc (ABTI) $4.85K -2005.32% 0.49x $603.58K
Aurora Cannabis Inc (ACB) $2.04 Billion -34.08% 0.34x $199.15 Million
Acreage Holdings Inc (ACRDF) $204.27 Million -30.85% 1.41x $13.48K
Acura Pharmaceuticals Inc (ACUR) $7.90 Million -63.15% 1.15x $13.20K
Agra Ventures Ltd. (AGFAF) $1.51 Million -44.22% 0.06x $298.23K
Allergy Therapeutics plc (AGYTF) $2.07 Million -2084.75% 31.32x $25.30 Million
Aida Pharmaceuticals Inc (AIDA) $6.67 Million 24.51% 2.78x $1.80
Adcock Ingram Holdings Limited (AIHLF) $3.07 Billion 20.55% 0.55x $85.61 Million